TH-302: Additional Phase I/II data

Additional data from 54 evaluable patients in the ongoing, open-label, dose-escalation Phase I/II TH-CR-403 trial showed that IV TH-302 plus doxorubicin produced 18 partial responses and 28 cases of s...